-
公开(公告)号：US20150266977A1
公开(公告)日：2015-09-24
申请号：US14625575
申请日：2015-02-18
Applicant: AbbVie Inc.
Inventor： Chung-Ming Hsieh , Alexander Ivanov , Wendy Waegell , Yulia Kutskova , John Memmott , Lorenzo Benatuil , Jacqueline Bixby , Emma Fung , Sahana Bose , Alyssa Brito
CPC classification number: C07K16/468 , A61K31/353 , A61K31/439 , A61K31/44 , A61K31/4439 , A61K31/519 , A61K31/56 , A61K38/13 , A61K38/1793 , A61K38/18 , A61K38/1808 , A61K38/1816 , A61K38/19 , A61K38/191 , A61K38/2026 , A61K38/2066 , A61K38/2073 , A61K38/217 , A61K39/3955 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/241 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2317/60 , C07K2317/64 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
Abstract translation: 与用于治疗，预防和诊断硬化性相关疾病的组合物和方法一起描述了结合硬化蛋白或硬化性骨肉瘤和TNF的蛋白质，并用于检测细胞，组织，样品和组合物中的硬化蛋白或硬化性骨肉瘤和TNF。
-
公开(公告)号：US11639390B2
公开(公告)日：2023-05-02
申请号：US17378565
申请日：2021-07-16
Applicant: AbbVie Inc.
Inventor： Jing Min , Teresa (Iok-Chan) Ng , Lorenzo Benatuil , Jacqueline Bixby , Tatyana Dekhtyar , Feng Dong , Axel Hernandez, Jr. , Preethi Krishnan , Liangjun Lu , Federico Mensa , Renee Miller , Gautam Sahu
IPC: C12N5/02 , C12N5/20 , C12N1/20 , C12N15/00 , C07K16/46 , C07K16/00 , C07H21/04 , C07K16/28 , A61P31/18 , C12N15/63 , A61K39/00
Abstract: The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.
-
公开(公告)号：US20220289858A1
公开(公告)日：2022-09-15
申请号：US17496476
申请日：2021-10-07
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Maria A. Argiriadi , Bradford L. Mcrae , Chung-Ming Hsieh , David A. Egan , John E. Harlan , Russell A. Judge , Rui Wang , Gillian A. Kingsbury
IPC: C07K16/28 , G01N33/566
Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
-
公开(公告)号：US20220017624A1
公开(公告)日：2022-01-20
申请号：US17378565
申请日：2021-07-16
Applicant: AbbVie Inc.
Inventor： Jing Min , Teresa (Iok-Chan) Ng , Lorenzo Benatuil , Jacqueline Bixby , Tatyana Dekhtyar , Feng Dong , Axel Hernandez, Jr. , Preethi Krishnan , Liangjun Lu , Federico Mensa , Renee Miller , Gautam Sahu
Abstract: The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.
-
公开(公告)号：US10174121B2
公开(公告)日：2019-01-08
申请号：US15167598
申请日：2016-05-27
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Bradford L. McRae , Chung-Ming Hsieh , Rui Wang
IPC: C07K16/28 , A61K39/395 , G01N33/566 , A61K39/00
Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
-
Patent Agency Ranking
公开(公告)号：US20180371071A1
公开(公告)日：2018-12-27
申请号：US15582065
申请日：2017-04-28
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
公开(公告)号：US20180094049A1
公开(公告)日：2018-04-05
申请号：US15785667
申请日：2017-10-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Stefan Barghorn , Heinz Hillen , Andreas Striebinger , Simone Giaisi , Ulrich Ebert , Lorenzo Benatuil
IPC: C07K16/18 , A61K47/68 , C07K14/47 , A61K49/00 , A61K39/395
CPC classification number: C07K16/18 , A61K39/3955 , A61K47/6835 , A61K49/00 , C07K14/4711 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/92
Abstract: The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
-
公开(公告)号：US09670276B2
公开(公告)日：2017-06-06
申请号：US13940506
申请日：2013-07-12
Applicant: AbbVie Inc.
Inventor： Susan E. Lacy , Lorenzo Benatuil , Meha Chhaya , Emma Fung , Renee Miller , Ravi Chari , Sarah J. Heighton , Jacqueline G. Bixby
IPC: C12P21/08 , A61K39/395 , C07K16/24 , A61K39/00
CPC classification number: C07K16/245 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/60 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.
-
公开(公告)号：US20170072065A1
公开(公告)日：2017-03-16
申请号：US15349692
申请日：2016-11-11
Applicant: AbbVie Inc.
Inventor： Edward B. Reilly , Andrew C. Phillips , Lorenzo Benatuil , Fritz G. Buchanan , Jonathan A. Meulbroek , Chung-Ming Hsieh , Jennifer Perez
CPC classification number: A61K47/6811 , A61K47/6803 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6863 , A61K47/6865 , A61K47/6889 , A61K2039/505 , C07K14/00 , C07K16/2863 , C07K16/30 , C07K16/3023 , C07K16/3046 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Abstract translation: 本发明涉及抗表皮生长因子（EGFR）抗体和抗体药物偶联物（ADC），包括使用所述抗体和ADC的组合物和方法。
-
公开(公告)号：US09550986B2
公开(公告)日：2017-01-24
申请号：US14136076
申请日：2013-12-20
Applicant: AbbVie, Inc.
Inventor： Feng Dong , Lorenzo Benatuil , Jijie Gu , Chung-Ming Hsieh
CPC classification number: C12N15/1089 , C07K16/465 , C40B30/02
Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.
Abstract translation: 本发明涉及用于抗体工程的改进方法，例如人源化。 具体地，本公开提供了可以通过计算机实现来自动化的高通量抗体人源化过程。
-
-
-
-
-
-
-
-
-
Search Results
44
records
(took 0.043 seconds)
